Neuromodulation by soy diets or equol: Anti-depressive & anti-obesity-like influences, age- & hormone-dependent effects

BMC Neuroscience

Volumn 12, Issue , 2011, Pages

  Blake, Crystal ^a   Fabick, Kimberly M ^a   Setchell, Kenneth D R ^b   Lund, Trent D ^c   Lephart, Edwin D ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c Stoelting Co   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUOL; ISOFLAVONE DERIVATIVE; PHYTO 600; SEROTONIN; UNCLASSIFIED DRUG; 4',7 DIHYDROXY 3,4 DIHYDROISOFLAVONE; 4',7-DIHYDROXY-3,4-DIHYDROISOFLAVONE; HORMONE; PHYTOESTROGEN; SOYBEAN PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIETARY INTAKE; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HORMONE DEPENDENCE; NEUROMODULATION; NONHUMAN; OBESITY; RAT; SEROTONIN BLOOD LEVEL; SOYBEAN; WEIGHT GAIN; WHITE ADIPOSE TISSUE; AGE; AGING; ANIMAL; BLOOD; BODY WEIGHT; CHEMISTRY; DIET THERAPY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; METABOLISM; METHODOLOGY; NONPARAMETRIC TEST; ORGAN SIZE; OVARIECTOMY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SWIMMING;

AGE FACTORS; AGING; ANIMALS; BODY WEIGHT; DEPRESSION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EQUOL; FEMALE; HORMONES; ISOFLAVONES; MALE; OBESITY; ORGAN SIZE; OVARIECTOMY; PHYTOESTROGENS; RATS; SEROTONIN; SOYBEAN PROTEINS; SOYBEANS; STATISTICS, NONPARAMETRIC; SWIMMING;

EID: 79952709089     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-12-28     Document Type: Article

References (60)

1. Pinkerton JV, Stovall DW, Kightlinger RS. Advances in the treatment of menopausal symptoms. Women's Health 2009, 5:361-384.
2. Henderson VW, Sherwin BB. Surgical verses natural menopause: cognitive issues. Menopause 2007, 14:572-579. 10.1097/gme.0b013e31803df49c, 17476147.
3. Writing Group for the WHI Investigators Risks and Benefits of Estrogen Plus Progestin in healthy Postmenopausal Women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397, Writing Group for the WHI Investigators.
4. Jamison JR. Clinical Guide To Nutrition and Dietary Supplements in Disease. 2003, Amsterdam, Netherland, Churchhill Livingstone/Elsevier.
5. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005, 81:23S-242S.
6. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol 1996, 87:897-904.
7. Oseni T, Patel R, Pyle J, Jordan VC. Selective estrogen receptor modulators and phytoestrogens. Planta Med 2008, 74:1656-1665. 10.1055/s-0028-1088304, 2587438, 18843590.
8. Kuiper GG, Lemmen JG, Carosson B, Orton JC, Safe SH, vad der Saag PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998, 139:4252-4263. 10.1210/en.139.10.4252, 9751507.
9. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med 1997, 29:95-120.
10. Muthyala RS, Ju YH, Sheng S, Williams LD, Doerge DR, Katzenellenbogen BS, Helferich WG, Katzenellenbogen JA. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem 2004, 12:1559-1567. 10.1016/j.bmc.2003.11.035, 15018930.
11. Setchell KD, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe BE, Nechemias-Zimmer L, Brown NM, Lund TD, Handa RJ, Heubi JE. S-Equol, a potent ligand for estrogen receptor {beta}, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005, 81:1072-1079.
12. World Health Organization Research on the Menopause in the 90 s. Technical Report Ser 866. 1996, Geneva, Switzerland: World Health Organization, World Health Organization.
13. Sowers MFR. The menopause transition and the aging process: A population perspective. Aging Clin Exp Res 2000, 12:85-92.
14. Landgren BM, Collins A, Csemiczky G, Burger HG, Baksheev L, Robertson DM. Menopause transition: Annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause. J Clin Endocrinol Metab 2004, 89:2763-2769. 10.1210/jc.2003-030824, 15181055.
15. Cheung E, Schwabish MA, Kraus WL. Chromatin exposes intrinsic differences in the transcriptional activities of estrogen receptors alpha and beta. EMBO J 2003, 22:600-611. 10.1093/emboj/cdg037, 140722, 12554660.
16. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA. Mechanisms of estrogen action. Physiol Rev 2001, 81:1535-1565.
17. Lund TD, Lephart ED. Dietary Soy Phytoestrogens Produce Anxiolytic Effects in The Elevated Plus-Maze. Brain Res 2001, 913:180-184. 10.1016/S0006-8993(01)02793-7, 11549384.
18. Lephart ED, Setchell KDR, Handa RJ, Lund TD. Behavioral Effects of Endocrine-distrupting Substances: Phytoestrogens. Inst Lab Animal Res Journal (National Academies USA) 2004, 45:443-454.
19. Lephart ED, Porter JP, Lund TD, Bu LH, Setchell KDR, Ramoz G, Crowley WR. Dietary isoflavones alter regulatory behaviors, metabolic hormones and neuroendocrine function in Long-Evans male rats. Metab Nutr 2004, 1:16.
20. Bu L, Lephart ED. Regulatory Behavior and Skin Temperature in Mid-Aged Male Rats on Three Different Isoflavone-Containing Diets. J Med Food 2006, 9:567-571. 10.1089/jmf.2006.9.567, 17201646.
21. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732. 10.1038/266730a0, 559941.
22. Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) 2005, 177:245-255. 10.1007/s00213-004-2048-7, 15609067.
23. van Meer P, Raber J. Mouse behavioural analysis in systems biology. Biochem J 2005, 389:593-610. 10.1042/BJ20042023, 1180709, 16035954.
24. Blake C, Fabick KM, Setchell KDR, Lund TD, Lephart ED. Prenatal Exposure to Equol Decreases Body Weight and Depressive-Like Behaviors In Male and Female Offspring. Curr Topics Nutr Res 2010, 8:69-78.
25. Friedman J, Frye C. Anti-anxiety, cognitive, and steroid biosynthetic effects of an isoflavone-based dietary supplement are gonad and sex-dependent in rats. Brain Res 2010,
26. Naaz A, Zakroczymski M, Heine P, Taylor J, Saunders P, Lubahn D, Cook PS. Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor alpha (ERα): a potential role for estrogen receptor beta (ERβ). Horm Metab Res 2002, 34:758-763. 10.1055/s-2002-38259, 12660895.
27. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006, 116:561-570. 10.1172/JCI27987, 2373424, 16511588.
28. Cederroth CR, Nef S. Soy, phytoestrogens and metabolism: A review. Mol Cell Endocrinol 2009, 304:30-42. 10.1016/j.mce.2009.02.027, 19433245.
29. Lindsay R, Dempster DW, Jordan VC, . (eds) Estrogens and Antiestrogens. 1997, New York: Lippincott-Raven, (eds).
30. Gentry RT, Wade GN. Sex differences in sensitivity of food intake, body weight, and running-wheel activity to ovarian steroids in rats. J Comp Physiol Psychol 1976, 90:747-754. 10.1037/h0077246, 965523.
31. Kim HK, Nelson-Dooley C, Della-Fera MA, Yang JY, Zhang W, Duan J, Hartzell DL, Hamrick MW, Baile CA. Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice. J Nutr 2006, 136:409-414.
32. Naaz A, Yellayi S, Zakroczymski MA, Bunick D, Doerge DR, Lubahn DB, Helferich WG, Cook PS. The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology 2003, 144:3315-3320. 10.1210/en.2003-0076, 12865308.
33. Dang Z, Lowik CW. The balance between concurrent activation of ERs and PPARs determines daidzein-induced osteogenesis and adipogenesis. J Bone Miner Res 2004, 19:853-861. 10.1359/jbmr.040120, 15068509.
34. Guo Y, Wu G, Su X, Yang H, Zhang J. Antiobesity action of a daidzein derivative on male obese mice induced by a high-fat diet. Nutr Res 2009, 29:656-663. 10.1016/j.nutres.2009.09.005, 19854381.
35. Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009, 9:51-60. 10.1586/14737140.9.1.51, 2785111, 19105706.
36. Anjaneyulu M, Chopra K, Kaur I. Antidepressant activity of quercetin, a bioflavonoid, in streptozotocin-induced diabetic mice. J Med Food 2003, 6:391-395. 10.1089/109662003772519976, 14977450.
37. Xu Y, Wang Z, You W, Zhang X, Li S, Barish PA, Vernon MM, Du X, Li G, Pan J, Ogle WO. Antidepressant-like effect of trans-resveratrol: Involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol 2010, 20:405-413. 10.1016/j.euroneuro.2010.02.013, 20353885.
38. Lephart ED, Hedges DW. Dementia, estrogen, and diet: a possible role of phytoestrogens (isoflavones) in Alzheimer's disease?. Focus on Alzheimer's Disease Research 2003, 51-68. New York: Nova Biomedical Books, Welsh EM.
39. Walf AA, Frye CA. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharm 2006, 31:1097-1111.
40. Walf AA, Frye CA. Rapid and estrogen receptor beta mediated actions in the hippocampus mediate some functional effects of estrogen. Steroids 2008, 73:997-1007. 10.1016/j.steroids.2008.01.025, 2459332, 18342348.
41. Sárvári M, Hrabovszky E, Kalló I, Galamb O, Solymosi N, Likó I, Molnár B, Tihanyi K, Szombathelyi Z, Liposits Z. Gene expression profiling identifies key estradiol targets in the frontal cortex of the rat. Endocrinology 2010, 151:1161-1176.
42. Lund TD, West TW, Tian LY, Bu LH, Simmons DL, Setchell KD, Adlercreutz H, Lephart ED. Visual spatial memory is enhanced in female rats (but inhibited in males) by dietary soy phytoestrogens. BMC Neurosci 2001, 2:20. 10.1186/1471-2202-2-20, 64558, 11801187.
43. Dewar D, Glover V, Elsworth J, Sandler M. Equol and other compounds from bovine urine as monoamine oxidase inhibitors. J Neural Transm 1986, 65:147-150. 10.1007/BF01256490, 3009710.
44. Amer DA, Kretzschmar G, Müller N, Stanke N, Lindemann D, Vollmer G. Activation of transgenic estrogen receptor-beta by selected phytoestrogens in a stably transduced rat serotonergic cell line. J Steroid Biochem Mol Biol 2010,
45. Sarrias MJ, Cabre P, Martinez E, Artigas F. Relationship between serotoninergic measures in blood and cerebrospinal fluid simultaneously obtained in humans. J Neurochem 1990, 54:783-786. 10.1111/j.1471-4159.1990.tb02319.x, 1689378.
46. Maurer-Spurej E, Pittendreigh C, Misri S. Platelet serotonin levels support depression scores for women with postpartum depression. J Psychiatry Neurosci 2007, 32:23-29. 1764545, 17245471.
47. Kovacic Z, Henigsberg N, Pivac N, Nedic G, Borovecki A. Platelet serotonin concentration and suicidal behavior in combat related posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:544-551. 10.1016/j.pnpbp.2007.10.014, 18055084.
48. Cleare A. Reduced whole blood serotonin in major depression. Depress Anxiety 1997, 5:108-111. 10.1002/(SICI)1520-6394(1997)5:2<108::AID-DA8>3.0.CO;2-B, 9262942.
49. Krezel W, Dupont S, Krust A, Chambon P, Chapman PF. Increased anxiety and synaptic plasticity in estrogen receptor β-deficient mice. PNAS 2001, 98:12278-12282. 10.1073/pnas.221451898, 59805, 11593044.
50. Walf AA, Frye CA. Administration of estrogen receptor beta-specific selective estrogen receptor modulators to the hippocampus decrease anxiety and depressive behavior of ovariectomized rats. Pharmacol Biochem Behav 2007, 86:407-414. 10.1016/j.pbb.2006.07.003, 16916539.
51. Lund TD, Rovis T, Chung WCJ, Handa RJ. Novel actions of estrogen receptor-β on anxiety-related behaviors. Endocrinology 2005, 146:797-807. 10.1210/en.2004-1158, 15514081.
52. Blardi P, de Lalla A, Leo A, Auteri A, Iapichino S, Di Muro A, Dell'Erba A, Castrogiovanni P. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J Clin Psychopharmacol 2002, 22:131-136. 10.1097/00004714-200204000-00005, 11910257.
53. Blardi P, de Lalla A, Auteri A, Iapichino S, Dell'Erba A, Castrogiovanni P. Plasma catecholamine levels after fluoxetine treatment in depressive patients. Neuropsychobiology 2005, 51:72-76. 10.1159/000084163, 15741747.
54. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH Consens State Sci Statements 2005, 22:1-38. NIH.
55. Maartens LW, Knottnerus JA, Pop VJ. Menopausal transition and increased depressive symptomatology: a community based prospective study. Maturitas 2003, 42:195-200.
56. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, Stefanick ML, McTiernan A. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes and Control 2002, 13:741-751. 10.1023/A:1020239211145, 12420953.
57. Yuksel H, Odabas AR, Demircan S, Koseoglu K, Kizilkaya K, Onur E. Effects of postmenopausal hormone replacement therapy on body fat composition. Gynecological Endocrinology 2007, 23:99-104. 10.1080/09513590601152177, 17454160.
58. Oktem O, Oktay K. Fertility Preservation for Breast Cancer Patients. Sem Reprod Med 2009, 27:486-492.
59. Lo Presti A, Ruvolo G, Gancitano RA, Cittadini E. Ovarian function following radiation and chemotherapy for cancer. Eur J Obstet Gynecol Reprod Biol 2004, 113:S33-40. 10.1016/j.ejogrb.2003.11.008, 15041128.
60. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas 2010, 65:161-166. 10.1016/j.maturitas.2009.08.003, 2815011, 19733988.